Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma

被引：0
|
作者：
Gil-Fernandez, Juan Jose [1 ,2 ]
Ramirez, Patricia Garcia [1 ]
Charavia, Marta Callejas [1 ]
机构：
[1] Univ Hosp Principe Asturias, Hematol Dept, Alcala De Henares, Spain
[2] Univ Hosp Principe Asturias, Hematol Dept, HU Principe Asturias, Madrid 28805, Spain
来源：
CLINICAL CASE REPORTS | 2024年 / 12卷 / 01期
关键词：
daratumumab-refractory myeloma; first-line therapy; isatuximab post daratumumab; newly diagnosed multiple myeloma;
D O I：
10.1002/ccr3.8449
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Derkach, Andriy
    Nemirovsky, David
    Ciardiello, Amanda
    Diamond, Benjamin
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Maclachlan, Kylee
    Patel, Dhwani
    Lahoud, Oscar B. B.
    Landau, Heather J. J.
    Chung, David J. J.
    Shah, Gunjan L. L.
    Scordo, Michael
    Giralt, Sergio A. A.
    Lesokhin, Alexander
    Usmani, Saad Z. Z.
    Landgren, Ola
    Korde, Neha
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [2] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Carlyn Rose Tan
    Andriy Derkach
    David Nemirovsky
    Amanda Ciardiello
    Benjamin Diamond
    Malin Hultcrantz
    Hani Hassoun
    Sham Mailankody
    Urvi Shah
    Kylee Maclachlan
    Dhwani Patel
    Oscar B. Lahoud
    Heather J. Landau
    David J. Chung
    Gunjan L. Shah
    Michael Scordo
    Sergio A. Giralt
    Alexander Lesokhin
    Saad Z. Usmani
    Ola Landgren
    Neha Korde
    Blood Cancer Journal, 13
  • [3] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Maclachlan, Kylee H.
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander
    Usmani, Saad Z.
    BLOOD, 2023, 142
  • [4] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Maclachlan, Kylee
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Usmani, Saad
    Lesokhin, Alexander
    Korde, Neha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
  • [5] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
    Tan, Carlyn
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Patel, Dhwani
    Maclachlan, Kylee H.
    Lahoud, Oscar B.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Korde, Neha
    Usmani, Saad
    BLOOD, 2022, 140 : 1817 - 1819
  • [6] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [7] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
    Leypoldt, Lisa B.
    Tichy, Diana
    Besemer, Britta
    Haenel, Mathias
    Raab, Marc S.
    Mann, Christoph
    Munder, Markus
    Reinhardt, Hans Christian
    Nogai, Axel
    Goerner, Martin
    Ko, Yon-Dschun
    de Wit, Maike
    Salwender, Hans
    Scheid, Christof
    Graeven, Ullrich
    Peceny, Rudolf
    Staib, Peter
    Dieing, Annette
    Einsele, Hermann
    Jauch, Anna
    Hundemer, Michael
    Zago, Manola
    Pozek, Ema
    Benner, Axel
    Bokemeyer, Carsten
    Goldschmidt, Hartmut
    Weisel, Katja C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 26 - +
  • [8] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
    Leleu, Xavier
    Hulin, Cyrille
    Lambert, Jerome
    Bobin, Arthur
    Perrot, Aurore
    Manier, Salomon
    Jaccard, Arnaud
    Montes, Lydia
    Karlin, Lionel
    Godmer, Pascal
    Chalopin, Thomas
    Slama, Borhane
    Chretien, Marie Lorraine
    Laribi, Karim
    Dingremont, Claire
    Roul, Christophe
    Mariette, Clara
    Rigaudeau, Sophie
    Macro, Margaret
    Mohty, Mohamad
    Touzeau, Cyrille
    Moreau, Philippe
    Avet-Loiseau, Herve
    Corre, Jill
    Facon, Thierry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
  • [9] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Derman, Ben A.
    Major, Ajay
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Alcantar, Luis
    Libao, Bernadette M.
    McIver, Amanda
    Andreatos, Evangelia
    Major, Sarah
    Wolfe, Brittany
    Gorski, Martha
    Karrison, Theodore G.
    Stefka, Andrew
    Jakubowiak, Andrzej
    BLOOD, 2021, 138
  • [10] Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis
    Costa, Bruno Almeida
    Costa, Thomaz Alexandre
    Pak, Kevin
    Patel, Aesha
    Felix, Nicole
    Mouhieddine, Tarek H.
    Richter, Joshua
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1411 - 1414
12345